Rate of Venous Thromboembolism Increased With Cancer Surgery
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 2, 2024 -- The rate of venous thromboembolism is increased in association with cancer surgery, according to a study published online Feb. 2 in JAMA Network Open.
Johan Björklund, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the one-year risk of venous thromboembolic events after major cancer surgery in a register-based retrospective observational matched cohort study. Patients who underwent major surgery for cancer of the bladder, breast, colon or rectum, gynecologic organs, kidney and upper urothelial tract, lung, prostate, or gastroesophageal tract were matched with cancer-free members of the general population in a 1:10 ratio (432,218 patients with cancer and 4,009,343 cancer-free comparators).
The researchers found that for all cancers, the crude one-year cumulative risk of pulmonary embolism was higher among the cancer surgery population, with absolute risk differences of 2.69, 0.59, 1.57, 1.32, 1.38, 2.61, 2.13, and 0.57 percentage points for bladder cancer, breast cancer, colorectal cancer, gynecologic organ cancer, kidney and upper urinary tract cancer, lung cancer, gastroesophageal cancer, and prostate cancer, respectively. Comparing patients who underwent cancer surgery with matched comparators, the cause-specific hazard ratio for pulmonary embolism peaked just after discharge and plateaued 60 to 90 days later. For all cancers except breast cancer, the hazard ratio was 10 to 30 times higher at 30 days after surgery. The hazards decreased but never reached the level of the comparison cohorts apart from prostate cancer.
"The results highlight the need for individualized venous thromboembolism risk evaluation and prophylaxis regimens for patients undergoing surgery for different cancers," the authors write.
Two authors disclosed ties to the pharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...
Odds of Death Lower With Surgery for Hip Fracture in Patients With Dementia
MONDAY, June 3, 2024 -- For community-dwelling patients with dementia and fracture of the femoral head and neck, the odds of death are lower for those treated surgically...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.